RT Journal Article
SR Electronic
T1 Update on cell therapy for stroke
JF Stroke and Vascular Neurology
FD BMJ Publishing Group Ltd
SP 59
OP 64
DO 10.1136/svn-2017-000070
VO 2
IS 2
A1 Cynthia L Kenmuir
A1 Lawrence R Wechsler
YR 2017
UL http://svn.bmj.com/content/2/2/59.abstract
AB Ischaemic stroke remains a leading cause of death and disability. Current stroke treatment options aim to minimise the damage from a pending stroke during the acute stroke period using intravenous thrombolytics and endovascular thrombectomy; however, there are no currently approved treatment options for reversing neurological damage once a stroke is completed. Preclinical studies suggest that cell therapy may be safe and effective in improving functional outcomes. Several recent clinical trials have reported safety and some improvement in outcomes following cell therapy administration in ischaemic stroke, which are reviewed. Cell therapy may provide a promising new treatment for stroke reducing stroke-related disability. Further investigation is needed to determine specific effects of cell therapy and to optimise cell delivery methods, cell dosing, type of cells used, timing of delivery, infarct size and location of infarct that are likely to benefit from cell therapy.